The Insider of KaloBios Pharmaceuticals Inc (NASDAQ:KBIO), Anthion Partners Ii Llc, Bought 713,726 Shares

Share with your friends










Submit

The Insider of KaloBios Pharmaceuticals Anthion Partners Ii Llc Bought 713726 Shares-Transactions

Anthion Partners Ii Llc Insider Buy Transaction

Anthion Partners Ii Llc is an insider of KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) . That well-know insider recently paid for 713,726 shares in the stock exchange listed company with the deal value totalling approximately $1.01 million USD. The stated number is according to the filing documented price of $1.4 for each one share. Details about the transaction dated 18/11/2015, could be found obtainable online in a public document on the SEC website here. The probability that this transaction remains ignored is quite small in view of the substantial amount of money involved. Today, Anthion Partners Ii Llc owns 1.16 million shares which are equivalent to around 29.53 % of the Company’s market cap (total dollar market value of all company’s outstanding shares).

Kalobios Pharmaceuticals Inc Stock Rating, Sentiment and Fundamentals

Today its obvious Anthion Partners Ii Llc is very optimistic about the California-based company’s stock prospects.

Rating & Sentiment
PsychSignal Social:SELL
Analysts Rating:BUY
Hedge Funds Sentiment:SELL
Stock Fundamentals
Earnings + FCF Trend:SELL
Sector/Industry Macro:BULLISH
Valuation Models:-
Technical Analysis
ST Trend:DOWN
MT Trend:DOWN
LT Trend:DOWN
OctaFinance Rating*:NEUTRAL

* Read How Our Stock Ratings System Works

We can’t rate the stock BUY only because of speculative reasons, our trend-following model doesn’t agree with this insider purchase. See the chart below. Over the last 25 days, Kalobios Pharmaceuticals Inc’s price per share has crashed 2.48 % and shows a steady downtrend.

Price Chart of Kalobios Pharmaceuticals NASDAQ:KBIO Stock

The Insider of KaloBios Pharmaceuticals Anthion Partners Ii Llc Bought 713726 Shares-Stock-Price-Chart

Source: RightEdgeSystems, Yahoo Split & Dividend Adjusted Data and OctaFinance Interpretations

Hedge Funds Ownership

Latest SEC filings disclose 17 hedge funds and other players own Kalobios Pharmaceuticals Inc. In the last quarter, Kalobios Pharmaceuticals Inc had 167.40 % institutional ownership. That is a low interest. They decreased by 1.96 million the total shares they hold. As of that quarter these institutional investors owned 6.90 million shares. There were 2 funds that created new positions and 3 funds that added to their positions. A total of 8 funds closed their positions in Kalobios Pharmaceuticals Inc and 3 reduced their holdings.

HEDGE-FUNDS-LIST-DATABASE-FREE

Harbourvest Partners Llc is the most positive institutional investor on Kalobios Pharmaceuticals Inc, with ownership of 57,604 shares as of Q2 2015 for 0.01% of the fund’s portfolio. Opus Point Partners Management Llc is another positive investment manager possessing 746,467 shares of the company or 0.28% of their stocks portfolio. The New Jersey-based fund Hallmark Capital Management Inc have less than 0.01% of their stock portfolio invested in the company for 15,861 shares. Further, The California-based fund Primecap Management Co Ca disclosed it had purchased a stake worth less than 0.01% of the fund’s stock portfolio in the company. The Pennsylvania-based fund Valley National Advisers Inc was also a notable believer in the company, owning 162 shares. Kalobios Pharmaceuticals Inc is less than 0.01% of the fund’s stock portfolio.

KaloBios Pharmaceuticals NASDAQ:KBIO Company Profile

KaloBios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of monoclonal antibody therapeutics for diseases that represent a burden to society and to patients and their families. The Company operates through the development of pharmaceutical products segment. The Company seeks to identify and develop products that may treat multiple indications through proof of concept studies. The Company’s principal pharmaceutical product candidates include: KB004, KB003 and KB001‑A. KB004 is a Humaneered anti EphA3 monoclonal antibody that has the potential to offer an approach to treating both hematologic malignancies and solid tumors. KB003 is a Humaneered anti granulocyte macrophage colony stimulating factor monoclonal antibody that was developed for the treatment of severe asthma. KB001-A is a Humaneered, PEGylated, anti PcrV modified antibody fragment antibody that was developed for the prevention and treatment of Pseudomonas aeruginosa infections.

Company Website: KaloBios Pharmaceuticals

At the moment its market cap is: $8.53 million and it has 3.93 million shares outstanding. Kalobios Pharmaceuticals Inc has 32 employees. As of writing there are 30.51% shareholders and the institutional ownership is 30.51%. Kalobios Pharmaceuticals Inc was formed in Delaware on 2001-09-19. The stock closed at $2.07 yesterday and it had average 2 days volume of 6206830 shares. It is up from the 30 days average shares volume of 608620. Kalobios Pharmaceuticals Inc has a 52 weeks low of $0.44 and a one year high of $16.00. The stock price is below the 200 days SMA. Kalobios Pharmaceuticals Inc last issued its quarterly earnings information on 08/10/2015. The company reported -1.46 EPS for the quarter, above the consensus estimate of -1.68 by 0.22. The company had a revenue of for 6/30/2015 and for 3/31/2015. Therefore, the revenue was down.

* The securities reported herein are owned directly by Anthion Partners II LLC and indirectly by David Moradi – the Managing Member of Anthion Partners II LLC. Both Anthion Partners II LLC and David Moradi are members of a “group” (with other persons) for purposes of Section 13(d) of the Securities Exchange Act of 1934. There is no voting or ownership agreement amongst the group members and the other members of the group do not have a pecuniary interest in the shares reported herein. Correspondingly – neither Anthion nor Mr. Moradi have a pecuniary interest in the shares owned by the other members of the group.

KaloBios Pharmaceuticals - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.